All In Biotech

Drug Trial Radar · NCT06514807

A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients

A Phase III, Single Arm, Multicentre Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients Who Are Intolerant or Refractory to or Not Eligible for Other Cytoreductive Treatments

Last checked: Nov 20, 2026Latest source record: Dec 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

117

Planned (sponsor's estimate)

Start

Dec 4, 2023

Primary completion

Mar 15, 2028

Study completion Mar 15, 2028

Sponsor

Lead sponsor
AOP Orphan Pharmaceuticals AGIndustry
Sponsor type
Industry
First posted
Jul 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the efficacy of ropeginterferon alfa-2b in patients with ET who need cytoreductive treatment but are intolerant or refractory to, and/or ineligible for cytoreductive treatments approved and available for the treatment of ET (i.e., HU, ANA, BUS, and PB, when they are available and approved for ET treatment). Ropeginterferon alfa-2b is currently the only interferon authorised as a cytoreductive treatment of a myeloproliferative neoplasm (MPN), and the long-term treatment data from its comprehensive clinical development program show its efficacy in the induction of haematologic remission, resolution of disease-associated symptoms, disease-modifying effect, as well as its favourable safety profile (Gisslinger et al., 2020; Kiladjian et al. 2022). Available clinical data and experience show that ropeginterferon alfa-2b normalises various haematological parameters, including platelets. In addition, suppression of the malignant clone causing ET may be achieved, at least after long-term treatment, which is expected to possibly defer the onset of, or avoid long-term sequelae of ET.

Conditions

  • Essential Thrombocythaemia

Interventions

  • Ropeginterferon alfa-2b (BESREMi®)Drug

    Ropeginterferon alfa-2b 250 micrograms/0.5 mL or 500 micrograms/0.5 ml solution for injection in pre-filled pen.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Durable (for at least 3 months) peripheral blood count remissionTime frame: At month 12
  2. Absence of haemorrhagic or thrombotic events and absence of disease progression*Time frame: At month 12
  3. Absence or Non-progression* in disease-related signsTime frame: At month 12
  4. Durable (for at least 3 months) large symptoms improvement or maintenance of non-progression based on the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)#Time frame: At month 12

Locations

36 sites in 10 countries. Site status is shown where the registry gives one.

  • Medical University Vienna, Department of Internal Medicine I, Clinical Department of Hematology and Hemostaseology

    Vienna, Austria

  • University Hospital Graz, Department of Internal Medicine, Clinical Department of Hematology

    Graz, Styria, Austria

  • Medical University Innsbruck, Department of Internal Medicine V (Hematology and Oncology)

    Innsbruck, Tyrol, Austria

  • Ordensklinikum Linz GmbH Elisabethinen Hospital, Department of Internal Medicine I - Hemato-Oncology

    Linz, Upper Austria, Austria

  • University Hospital Brno, Clinic of Internal Medicine - Hematology and Oncology

    Brno, Czechia

  • University Hospital Kralovske Vinohrady, Clinic of Internal Hematology

    Prague, Czechia

  • Saint-Louis Hospital, Department of Adult Hematology

    Paris, France

  • Bordeaux University Hospital, Haut-Leveque Hospital

    Pessac, France

  • Centre Hospitalier Universitaire De Poitiers

    Poitiers, Poitiers, France

  • University Hospital Aachen, Clinic of Oncology, Hematology and Stem Cell Transplantation (Medical Clinic IV)

    Aachen, Germany

  • University Hospital Halle (Saale), Department of Internal Medicine IV - Hematology and Oncology

    Halle, Germany

  • Hannover Medical School, Clinic for haematology, haemostaseology, oncology and stem cell transplantation

    Hanover, Germany

  • University Hospital Mannheim, Medical Clinic III, Hematology and Internistic Oncology

    Mannheim, Germany

  • Johannes Wesling Hospital Minden, Department of Oncology and Hematology

    Minden, Germany

  • University Hospital Ulm, Center for Internal Medicine, Clinic of Internal Medicine III, Department of Hematology, Oncology, Rheumatology, Infectious Diseases

    Ulm, Germany

  • General Hospital of Athens Alexandra, Therapeutic Clinic, Department of Therapeutics

    Athens, Greece

  • University General Hospital "Attikon"

    Athens, Greece

  • Semmelweis University, Department of Internal Medicine and Haematology, Division of Hematology

    Budapest, Hungary

  • University of Debrecen Clinical Center, Clinic of Internal Medicine, Department of Hematology

    Debrecen, Hungary

  • Polyclinic S. Orsola-Malpighi

    Bologna, Italy

  • Careggi University Hospital, Department of Hematology

    Florence, Italy

  • Umberto I Polyclinic of Rome

    Rome, Italy

  • University Polyclinic Foundation "Agostino Gemelli" - IRCCS, Service of Hematology

    Rome, Italy

  • University Hospital City of Health and Science of Turin - Hospital Molinette, Complex Structure of Hematology - U

    Turin, Italy

  • University Teaching Centre, Hematology and Transplantology Clinic

    Gdansk, Poland

  • Pratia Oncology Katowice

    Katowice, Poland

  • Independent Public Healthcare Facility University Hospital in Krakow, Teaching Unit of the Hematology Department

    Krakow, Poland

  • Nicolaus Copernicus Provincial Multispecialty Oncology and Traumatology Center in Lodz, Department of Hematooncology with Subdivision of Daytime Chemotherapy

    Lodz, Poland

  • Onco Card Srl

    Brasov, Romania

  • "Prof. Dr. Ion Chiricuta" Institute of Oncology, Hematology Department

    Cluj-Napoca, Romania

  • Fundeni Clinical Institute, Center for Hematology and Bone Marrow Transplantation

    Crişan, Romania

  • Iasi Regional Institute of Oncology, Department of Hematology

    Iași, Romania

  • University Hospital Germans Trias i Pujol

    Badalona, Spain

  • Hospital Clinic of Barcelona, Department of Hematology

    Barcelona, Spain

  • University Hospital Ramon y Cajal, Hematology Service

    Madrid, Spain

  • Morales Meseguer University General Hospital

    Murcia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.